Analysts Set Anthera Pharmaceuticals Inc (ANTH) Price Target at $5.25

Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) have been assigned a consensus rating of “Hold” from the six analysts that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $5.25.

A number of research firms recently commented on ANTH. Zacks Investment Research lowered shares of Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, February 28th. ValuEngine raised shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, December 31st. Piper Jaffray lowered shares of Anthera Pharmaceuticals from an “overweight” rating to an “underweight” rating in a research note on Monday, March 12th. Roth Capital began coverage on shares of Anthera Pharmaceuticals in a research note on Wednesday, February 21st. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Jefferies Group reaffirmed a “hold” rating and issued a $0.50 price objective on shares of Anthera Pharmaceuticals in a research note on Thursday, March 15th.

How to Become a New Pot Stock Millionaire

Anthera Pharmaceuticals stock traded down $0.01 during midday trading on Thursday, reaching $0.33. The stock had a trading volume of 684,618 shares, compared to its average volume of 2,654,308. Anthera Pharmaceuticals has a twelve month low of $0.30 and a twelve month high of $3.36. The firm has a market capitalization of $8.19, a price-to-earnings ratio of -0.09 and a beta of 2.78.

Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its quarterly earnings data on Monday, March 5th. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.09. equities analysts expect that Anthera Pharmaceuticals will post -2.28 earnings per share for the current year.

Several large investors have recently modified their holdings of the business. BVF Inc. IL boosted its stake in shares of Anthera Pharmaceuticals by 20.9% during the 4th quarter. BVF Inc. IL now owns 1,216,403 shares of the biopharmaceutical company’s stock valued at $2,007,000 after buying an additional 209,896 shares during the period. Armistice Capital LLC acquired a new stake in shares of Anthera Pharmaceuticals during the 4th quarter valued at $1,269,000. Finally, 683 Capital Management LLC acquired a new stake in shares of Anthera Pharmaceuticals during the 4th quarter valued at $399,000. 16.65% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Analysts Set Anthera Pharmaceuticals Inc (ANTH) Price Target at $5.25” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://sportsperspectives.com/2018/04/17/analysts-set-anthera-pharmaceuticals-inc-anth-price-target-at-5-25.html.

Anthera Pharmaceuticals Company Profile

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply